➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
Johnson and Johnson
Merck
Harvard Business School
Baxter
Express Scripts

Last Updated: October 18, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TECOVIRIMAT

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Tecovirimat

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00431951 ↗ Phase I, Escalating, Multiple-Dose, ST-246 Safety, Tolerability and Pharmacokinetics 21-Day Trial in Healthy Volunteers Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 1 2007-02-01 The purpose of this study was to assess the safety, tolerability, and pharmacokinetics of a single, daily, oral dose of ST-246 (either 250, 400 or 800mg) administered for 21 days to 30 healthy, fed volunteers.
NCT00431951 ↗ Phase I, Escalating, Multiple-Dose, ST-246 Safety, Tolerability and Pharmacokinetics 21-Day Trial in Healthy Volunteers Completed SIGA Technologies Phase 1 2007-02-01 The purpose of this study was to assess the safety, tolerability, and pharmacokinetics of a single, daily, oral dose of ST-246 (either 250, 400 or 800mg) administered for 21 days to 30 healthy, fed volunteers.
NCT00728689 ↗ Phase I Trial of an Investigational Small Pox Medication Completed National Institutes of Health (NIH) Phase 1 2008-08-01 The purpose of this study was to evaluate the pharmacokinetic parameters and safety of a single dose of ST-246 400mg Form I versus ST-246 400mg Form V capsules in fed normal healthy volunteers.
NCT00728689 ↗ Phase I Trial of an Investigational Small Pox Medication Completed SIGA Technologies Phase 1 2008-08-01 The purpose of this study was to evaluate the pharmacokinetic parameters and safety of a single dose of ST-246 400mg Form I versus ST-246 400mg Form V capsules in fed normal healthy volunteers.
NCT00907803 ↗ Safety, Tolerability, Pharmacokinetics (PK) of the Anti-Orthopox Drug, ST-246 Completed National Institutes of Health (NIH) Phase 2 2009-06-01 The purpose of this study was to assess the safety, tolerability, and pharmacokinetics of two clinical doses of the anti-orthopoxvirus drug, ST-246, administered as a single daily oral dose for 14 days to healthy, fed volunteers. The results of this trial determine which dose will be used in expanded pivotal safety trials.
NCT00907803 ↗ Safety, Tolerability, Pharmacokinetics (PK) of the Anti-Orthopox Drug, ST-246 Completed SIGA Technologies Phase 2 2009-06-01 The purpose of this study was to assess the safety, tolerability, and pharmacokinetics of two clinical doses of the anti-orthopoxvirus drug, ST-246, administered as a single daily oral dose for 14 days to healthy, fed volunteers. The results of this trial determine which dose will be used in expanded pivotal safety trials.
NCT02080767 ↗ Tecovirimat (ST-246) Treatment for Orthopox Virus Exposure Available U.S. Army Medical Research and Materiel Command N/A 1969-12-31 The purpose of this clinical protocol is to treat individuals with Tecovirimat after exposure to orthopox viruses.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Tecovirimat

Condition Name

Condition Name for Tecovirimat
Intervention Trials
Smallpox 4
Orthopoxviral Disease 2
Monkeypox 1
Monkey Pox 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Tecovirimat
Intervention Trials
Smallpox 4
Monkeypox 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Tecovirimat

Trials by Country

Trials by Country for Tecovirimat
Location Trials
United States 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Tecovirimat
Location Trials
Florida 3
California 2
Texas 1
South Carolina 1
Nebraska 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Tecovirimat

Clinical Trial Phase

Clinical Trial Phase for Tecovirimat
Clinical Trial Phase Trials
Phase 3 2
Phase 2 1
Phase 1 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Tecovirimat
Clinical Trial Phase Trials
Completed 3
Available 1
Not yet recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Tecovirimat

Sponsor Name

Sponsor Name for Tecovirimat
Sponsor Trials
SIGA Technologies 5
Biomedical Advanced Research and Development Authority 2
National Institutes of Health (NIH) 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Tecovirimat
Sponsor Trials
Industry 5
NIH 3
U.S. Fed 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Medtronic
Dow
Mallinckrodt
McKinsey
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.